

SIMPLIVIA™ Incorporates Tevadaptor® Activity



Tevadaptor is a premium Closed System Transfer Device (CSTD) for safe compounding, administration and handling of hazardous drugs, keeping Pharmacists, Nurses, Veterinarians and other Healthcare workers safe.

We are pleased to announce that as of May 1st Simplivia Healthcare LTD, incorporates the Tevadaptor® global business and manufacturing activity.

The company is owned by Fimi opportunity fund - one of the top 5 investment funds in the world in terms of consistency of performance.

Tevadaptor® is a closed system transfer device (CSTD) for safe compounding and administration. It minimizes the risk of exposure to hazardous drugs. such as those found in Oncology, alongside maintaining drug sterility and eliminating the risk of needle-stick injuries, keeping pharmacists, nurses and patients safe.

Tevadaptor®'s patented TOXI-GUARD® system, located in the vial adaptor, allows pressure equalization during use, prevents the escape of hazardous drug vapors into the environment during drug reconstitution and administration and prevents airborne contaminants and particles from entering the drug vial.

Tevadaptor® has a CE mark and is FDA cleared under the ONB product code, meeting NIOSH CSTD definitions - a Closed System Transfer Device that mechanically prohibits the release of the drug in vapor, aerosol or liquid form during preparation and administration.

Tevadaptor® is manufactured with the highest quality standards (MDD, EN ISO 13485, FDA and JP regulation). Launched in 2005, Tevadaptor® is currently selling in more than 25 countries. With presence in world leading markets, such as US, Japan, large EU markets and more, Tevadaptor® continues to expand to new markets worldwide.

Tevadaptor® is easy to use and intuitive. This, together with a low number of SKU's, which cover all product applications, make it user friendly, compliant and easy to store and manage.

Tevadaptor® is an innovative medical device developed by Teva Medical, covering a large range of users-Pharmacists, Nurses, Research labs, Veterinarians and any others working with hazardous drugs.

Tevadaptor® enables cost saving of expensive drugs by maintaining drug sterility and stability¹, and reducing drug wastage².

Wilkinson AS. Evaluation of the Physicochemical and Functional Stability of Trastuzumab™ (TZM) Following Reconstitution and Extended

Storage in a Closed System Transfer Device (CSTD), TEVADAPTOR® for up to 28 Days. Presented at EAHP 2016.

Juhász A, Batka G, Szűcs A. Responding to Drug Shortages and Rising Costs: IV Chemotherapy Drug Use Optimization Achieved by Closed Safety Devices in Hospital Pharmacies. Drugs Ther Perspect. 2016; 32(4):170-176